Posters

      Reduced Exposure To Harmful And Potentially Harmful Constituents After Five Days of Use of Tobacco Heating System 2.2: A Comparison with Continued Combustible Cigarette Use or Smoking Abstinence [Poland]

      Haziza, C.; de La Bourdonnaye, G.; Picavet, P.; Baker, G.; Skiada, D.; Ancerewicz, J. Ancerewicz.; Jarus-Dziedzic, K.; Lüdicke, F.

      Conference date
      Feb 28, 2015
      Conference name
      Society for Research on Nicotine and Tobacco (SRNT) 2015
      Link to more information
      Link to more information
      Topic
      Summary

      The Tobacco Heating System (THS) 2.2 was developed to reduce or eliminate the formation of harmful and potentially harmful smoke constituents (HPHCs) in the aerosol through heating and not burning tobacco, while preserving as much as possible the taste, sensory experience, nicotine delivery profile and ritual characteristics of combustible cigarettes (CC). The study reported here is part of a global clinical program for THS 2.2 and was designed to demonstrate exposure reduction to selected HPHCs when switching from CC to THS 2.2 use in a controlled setting for 5 days, compared to those continuing to smoke CC. Smokers who abstained from smoking were used as a benchmark. The BoExp measured in this study represent 14 HPHCs, considered to provide a representative assessment of human uptake of a variety of toxicants and carcinogens in tobacco-products.This study also included endpoints to investigate the acceptance of THS 2.2 as a substitute to CC through assessment of subjective effects (questionnaire of smoking urges-Brief [QSU-Brief]; modified cigarette evaluation questionnaire [mCEQ]).

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.